Urinary Incontinence (Female) Algorithm

1

Safety

Red Flags — Exclude Serious Pathology First

Done

Screen for sinister causes of urinary symptoms before managing as benign UI. Do not assume all urinary symptoms are simply "incontinence".

Haematuria (frank or microscopic) Blood in urine at any age → Urgent 2WW urology referral (bladder/renal malignancy)

Painless haematuria + UI Bladder carcinoma can present with urgency → 2WW Urology

New neurological symptoms Leg weakness, saddle anaesthesia, bilateral leg symptoms → 999 / Same-day MRI (cauda equina)

Faecal incontinence co-existing Dual sphincter involvement → Same-day neurosurgery review if acute onset (cauda equina syndrome)

Pelvic mass on examination Palpable bladder, pelvic organ, or rectal mass → 2WW gynaecology/urology

Recurrent UTIs (≥3 in 12 months) Especially post-menopausal or with haematuria → 2WW urology (malignancy)

Urinary retention with overflow Constant dribbling, large post-void residual → Same-day urology (retention causing renal damage)

Systemic features Unexplained weight loss, night sweats with UI → 2WW investigation (malignancy)

Acute-onset in post-menopausal female New onset urgency without prior history → Exclude malignancy, infection, neurological cause

Bladder cancer presents with painless haematuria ± urgency in up to 20% of cases — missing this is a serious SCA failure. Cauda equina syndrome can present subacutely with urinary incontinence, saddle anaesthesia, and bilateral leg weakness; missing this causes permanent paralysis. NICE NG12 mandates 2WW for haematuria (visible or non-visible) in females ≥60. Overflow incontinence secondary to retention can cause acute kidney injury if untreated. Always examine abdominally and perform urinalysis before labelling as stress/urge UI.

2

Diagnose

History-Based Type Classification — Stress vs Urgency vs Mixed

Done

The history alone classifies UI type in most cases. Use a structured approach — treatment differs fundamentally by subtype.

Stress UI (SUI)

Leakage on coughing, sneezing, laughing, exercise, lifting. No preceding urge sensation. Typically small volumes. Most common type in younger women

Urgency UI (UUI)

Sudden compelling urge to void followed by uncontrolled leakage. Often cannot reach toilet in time. Key: urgency precedes leak. OAB syndrome

Mixed UI

Symptoms of both SUI and UUI. Identify which is predominant — this guides first treatment. Common in older women

Overflow UI

Constant dribbling, incomplete bladder emptying, straining to void. Consider if: previous pelvic surgery, neurological disease, severe prolapse. Refer

Functional UI

Unable to reach toilet due to mobility/cognitive issues rather than bladder pathology. Assess with MMSE, mobility assessment.

Key questions

Frequency, nocturia, pad use per day, quality of life impact (ICI-Q-SF score), duration, obstetric history, menopausal status, medications (diuretics, ACEi cough), fluid intake, caffeine intake

ICI-Q-SF Score

Validated 3-question tool. Frequency + volume + impact. Score 1–5 mild, 6–12 moderate, 13–18 severe, 19–21 very severe. Use to guide management and monitor treatment response.

Bladder diary

Request 3-day bladder diary: times voided, volumes, leakage episodes, urgency severity, fluid intake. Essential before specialist referral and guides behavioural therapy targets.

History accurately classifies UI type in ~75% of cases (NICE NG123). Distinguishing SUI from UUI is critical because pelvic floor exercises are first-line for SUI, while bladder training + antimuscarinics are first-line for UUI. Using the wrong treatment not only fails the patient but wastes NHS resources. The ICI-Q-SF is recommended by NICE as an objective measure of symptom severity. The 3-day bladder diary reveals patterns (nocturnal polyuria, excessive fluid intake, caffeine effect) that significantly change management.

3

Diagnose

Exclude Reversible Causes — DIAPPERS Mnemonic

Done

Up to 30% of UI has a reversible cause. Treat these before labelling as primary UI. Use DIAPPERS mnemonic.

D — Delirium

Acute confusion causing inability to recognise or respond to urge. Address underlying cause.

I — Infection

UTI causing transient urgency/frequency. Always dipstick urine. If positive: MSU + treat. Dipstick + MSU

A — Atrophic vaginitis

Post-menopausal oestrogen deficiency causing urogenital atrophy → urgency, frequency, dysuria. Examine: pale/dry vaginal mucosa. Treat with topical oestrogen.

P — Pharmacological

Diuretics (urgency), ACE inhibitors (cough → SUI), antipsychotics (retention→overflow), opioids (retention). Review medication list every time.

P — Psychological

Anxiety, depression, severe mental illness. Consider if functional aetiology dominates history.

E — Endocrine

Diabetes mellitus (polyuria, UTIs), diabetes insipidus (high volumes). Check HbA1c in new presentations.

R — Restricted mobility

Cannot reach toilet in time → functional incontinence. Physiotherapy, walking aids, commode near bed.

S — Stool impaction

Faecal loading causes detrusor instability → urgency. PR exam / history of constipation. Treat constipation first.

Urinalysis (mandatory)

Dipstick all patients. Nitrites + leucocytes → MSU for culture. Blood → haematuria pathway. Glucose → diabetes screen. Protein → renal disease. Always do this

NICE NG123 emphasises excluding reversible causes before initiating treatment for UI. UTI is the most common reversible cause and will not respond to pelvic floor exercises. Atrophic vaginitis is under-recognised — topical oestrogen (vagifem/ovestin) resolves symptoms in 60–80% of cases within 3 months with minimal systemic absorption. ACE inhibitor cough causes significant SUI through repeated Valsalva — switching to an ARB resolves this. These reversible causes are classic SCA examination traps.

4

Diagnose

Targeted Examination — Abdominal, Pelvic, Neurological

Done

Examination in primary care should be targeted and purposeful. A chaperone is always required for pelvic examination.

Abdominal exam

Palpate suprapubic area: distended bladder suggests retention/overflow. Palpate for pelvic masses. Percuss for dullness (full bladder). Distended bladder → refer urgently

BMI

Calculate BMI. Obesity (BMI >30) is an independent risk factor for SUI — weight loss 5–10% significantly improves symptoms. Weight loss target

Vaginal / perineal exam

Signs of atrophy (pale, thin, dry mucosa). Pelvic organ prolapse (POP): ask patient to cough/strain, observe for cystocele, rectocele, vault prolapse. Grade POP if present (POP-Q or Baden-Walker). Exclude fistula (constant leakage).

Stress test

Ask patient to cough with full bladder (standing preferred). Observe urethral meatus for immediate leakage on cough → confirms SUI. Delayed leakage suggests UUI. Diagnostic test for SUI

Neurological screen

Perianal sensation (S2–S4 dermatome), anal tone (digital PR if indicated). Lower limb reflexes (absent ankle jerks → peripheral neuropathy → overflow risk). Upper motor neurone signs → refer neurology.

Pelvic floor assessment

Modified Oxford scale (0–5) if trained: assesses pelvic floor contraction strength. Grade 0 = no contraction, Grade 5 = strong contraction against resistance. Guides PFMT intensity. Specialist PFMT often needed

Post-void residual

Bladder scan after voiding in primary care (if available) or refer for USS. PVR >150 ml suggests voiding dysfunction / retention. Refer if elevated. Bladder scan PVR

Examination changes management in a significant proportion of patients. POP grade ≥3 requires gynaecology referral before initiating conservative treatment. The cough stress test has 86% sensitivity for SUI when performed with a full bladder. Atrophic vaginitis is only identified on examination — many patients do not spontaneously report vaginal symptoms. Neurological examination screens for cord compression, multiple sclerosis, and diabetic autonomic neuropathy — all of which require different management pathways.

5

Diagnose

Investigations — What to Order and When

Done

Most UI is managed in primary care without extensive investigation. Investigate selectively — only when it will change management.

Urinalysis (all)

Mandatory Dipstick ± MSU. See Step 3. If haematuria → send MSU + refer 2WW urology regardless of other findings.

MSU for culture

If dipstick suggests UTI (nitrites ± leucocytes), or recurrent UTIs. Do NOT treat asymptomatic bacteriuria in non-pregnant women. Avoid over-treatment

3-day bladder diary

Request at first consultation. Assess total daily volumes (<1.5 L suggests under-hydration), voiding frequency (<8 times/day is normal), nocturnal episodes, leakage triggers. Essential for diagnosis + monitoring

HbA1c

If polyuria, polydipsia, recurrent infections, or risk factors for diabetes. Uncontrolled diabetes causes osmotic diuresis mimicking OAB.

Renal function (U&E)

If recurrent UTIs, suspected retention, hypertension, or before starting antimuscarinics in elderly (CKD affects drug clearance).

Post-void residual USS

If suspected overflow (constant dribbling, straining to void, pelvic surgery history, neurological disease). PVR >150 ml → refer urology/urogynaecology.

Urodynamics

Specialist only Cystometry, uroflowmetry — NOT routinely in primary care. Refer if: diagnosis unclear after history + examination, failed primary care treatment, before surgical intervention, suspected voiding dysfunction.

Do NOT routinely order

Cystoscopy, urodynamics, renal USS — these are specialist investigations. Primary care management does not require them for uncomplicated SUI/UUI.

NICE NG123 recommends against routine urodynamics in primary care — it adds cost and delay without changing initial management. The bladder diary is the most valuable diagnostic tool in primary care: it reveals nocturnal polyuria (which needs desmopressin, not antimuscarinics), excessive caffeine intake (reducing to <200 mg/day reduces urgency episodes by ~30%), and true voiding frequency. MSU before treating UI is mandatory — treating UI with antimuscarinics when the patient actually has a UTI is a common and avoidable error.

6

Refer

Referral Criteria — Who Needs Specialist Input

Done

Most female UI is managed entirely in primary care. Refer selectively when primary care treatment fails or red flags are present.

Same-day / 999

Acute urinary retention (unable to void, suprapubic pain, distended bladder). New neurological symptoms + UI (cauda equina). Suspected sepsis with urinary source.

2WW Urology

Haematuria (visible or non-visible on two occasions) at any age. Recurrent UTIs ≥3 in 12 months, especially if post-menopausal. Suspected bladder/urethral malignancy. Age ≥45 with unexplained haematuria + dysuria.

2WW Gynaecology

Pelvic mass identified on examination. Post-menopausal bleeding with UI (exclude endometrial malignancy).

Routine Urogynaecology

Failed ≥3 months conservative management (PFMT + bladder training). Suspected complex UI requiring urodynamics. Significant pelvic organ prolapse (grade ≥3) co-existing with UI. Considering surgical intervention. Previous pelvic surgery/radiotherapy.

Routine Urology (female)

Recurrent UTIs with no clear cause. Suspected vesico-vaginal fistula (constant wetness, no urge). PVR >150 ml on two occasions. Voiding dysfunction not resolving.

Continence nurse specialist

Refer for supervised PFMT if symptoms moderate–severe (ICI-Q ≥6) before drug treatment. Often more effective than GP-led advice alone

Primary care manages

Uncomplicated SUI with normal examination. UUI without haematuria or pelvic mass. Mixed UI — treat dominant component first. Mild symptoms (ICI-Q ≤5) — conservative first.

The majority of UI in primary care responds to conservative management without specialist referral. NICE NG123 supports primary care management for uncomplicated SUI and UUI. Continence nurse specialists provide supervised PFMT programmes — evidence shows this is significantly more effective than written leaflet advice alone (Cochrane 2018: RR 0.87 for cure/improvement with supervised vs unsupervised PFMT). Knowing when not to refer is as important as knowing when to refer — unnecessary referral delays access for patients who genuinely need specialist care.

7

Treat

Treatment Pathway — Type-Specific Stepwise Approach

Done

Treatment is type-specific. Treat SUI and UUI differently. Address reversible causes first (Step 3). Offer lifestyle measures alongside all pharmacological treatment (Step 8).

▸ STRESS URINARY INCONTINENCE (SUI)

Step 1Supervised Pelvic Floor Muscle Training (PFMT) — Minimum 3 months before offering pharmacological treatment. ≥8 contractions × 3 sets daily. Refer to continence nurse/physiotherapist for supervised programme. First-line

Step 2Duloxetine (SNRI) — if PFMT declined or inadequate response and patient not planning surgery. 40 mg BD (start 20 mg BD × 2 weeks to reduce nausea). Warn: nausea (most common), discontinue syndrome if stopped abruptly. Duloxetine 40 mg BD Not first-line — offer as adjunct or if surgery declined

Step 3Surgical referral via urogynaecology — if conservative measures fail after ≥3 months. Options include: mid-urethral sling (TVT/TOT), colposuspension, bulking agents. Counsel regarding risks (mesh complications — NICE guidance 2019). Refer Urogynaecology

▸ URGENCY URINARY INCONTINENCE / OAB (UUI)

Step 1Bladder retraining — Minimum 6 weeks. Progressively increase voiding intervals by 15 minutes each week, targeting ≥3-hour intervals. Combined with fluid management and urgency suppression techniques (e.g. distraction, perineal pressure). First-line

Step 2Antimuscarinic (anticholinergic) drugs — if bladder training alone insufficient after 6 weeks. Start with:

Preferred first choice (lower CNS penetration)

Solifenacin 5 mg OD

Increase to 10 mg OD if inadequate response at 4 weeks. Lower cognitive side-effect profile vs oxybutynin. Review at 4 weeks.

Alternative if solifenacin not tolerated

Tolterodine 2 mg BD

Or tolterodine MR 4 mg OD. Similar efficacy to solifenacin. Monitor for side effects: dry mouth, constipation, blurred vision, urinary retention.

Avoid in elderly / cognitive risk

Oxybutynin Avoid if possible

High CNS penetration → cognitive impairment, confusion. NICE 2023: avoid oxybutynin in elderly due to dementia risk. If used: immediate release 2.5–5 mg TDS.

Step 3Mirabegron (beta-3 agonist) — 50 mg OD. Use if antimuscarinics are contraindicated, not tolerated, or ineffective. Contraindications: uncontrolled hypertension (BP >180/110). Monitor BP before starting. Mirabegron 50 mg OD No anticholinergic effects — preferred in elderly

Step 3bMirabegron + antimuscarinic combination (specialist-initiated) — if monotherapy inadequate. Increased risk of urinary retention — ensure PVR checked.

Step 4Specialist referral for third-line: Botulinum toxin A intravesical injection (onabotulinumtoxinA 100 units) — effective for 6–9 months. Sacral nerve stimulation (neuromodulation). Percutaneous tibial nerve stimulation (PTNS). Refer Urogynaecology/Urology

▸ ATROPHIC VAGINITIS / GENITOURINARY SYNDROME OF MENOPAUSE (GSM)

First-lineTopical vaginal oestrogen — Vagifem (estradiol 10 mcg) pessary OD × 2 weeks then twice weekly. Or Ovestin cream 0.5 mg OD × 2–3 weeks then twice weekly. Long-term use is safe (minimal systemic absorption). No need to add progestogen for topical vaginal oestrogen. Vagifem 10 mcg pessary

AlternativeSystemic HRT — if GSM plus vasomotor symptoms. Discuss risks/benefits per NICE NG23. Consider combined HRT for women with intact uterus.

PFMT evidence: Cochrane 2018 (Dumoulin et al.) — PFMT significantly more effective than no treatment for cure of SUI (RR 8.38). 3-month minimum is needed to see benefit. Duloxetine NNT for 50% reduction in leakage episodes is ~3, but 50% discontinue due to nausea — counsel carefully. Antimuscarinics: NNT for 1 extra "dry" day per week vs placebo ~5. MHRA 2021 alert: long-term anticholinergic use (especially oxybutynin) associated with dementia risk — minimise use in elderly. Mirabegron avoids this risk and is now preferred first-line in older women (NICE 2023 update). Botulinum toxin A has 70–80% response rate in UUI refractory to oral treatment, lasting 6–9 months.

8

Lifestyle

Non-Pharmacological Interventions — Evidence-Based Targets

Done

Lifestyle modification is core treatment, not an afterthought. Offer alongside all pharmacological and surgical options. Quantify impact for patient motivation.

Weight loss BMI >30: lose 5–10% body weight. Reduces UI episodes by 50–60% in obese women (PRIDE trial). Refer to NHS weight management programme. Target: 5 kg minimum.

Fluid management Target 1.5–2 L/day. Avoid under-drinking (concentrated urine irritates bladder → worsens urgency). Avoid excess. Spread intake throughout the day; reduce after 6 pm for nocturia.

Caffeine reduction Reduce to <200 mg/day (≈2 standard coffees). Caffeine is a bladder irritant — reduction decreases urgency episodes by ~25–30%. Switch to decaffeinated. Document caffeine intake from bladder diary.

Smoking cessation Smoking causes chronic cough → worsens SUI. Reduces risk of bladder malignancy. Refer to NHS Stop Smoking Service. Nicotine replacement / varenicline.

Constipation management Straining worsens pelvic floor dysfunction. Increase dietary fibre, hydration, regular toilet routine. Lactulose / Movicol if needed. Faecal loading directly causes detrusor instability.

Pelvic floor exercises (self-directed) 8 sustained contractions (10 seconds each) × 3 sets × daily. Minimum 3 months for SUI. Advise: contract before coughing/sneezing (The Knack manoeuvre). Free NHS apps available (Squeezy app).

Bladder retraining For UUI: hold on urgency using distraction / perineal pressure. Progressively delay voiding by 15 min/week. Target: void every 3–4 hours. Supported by written bladder retraining programme leaflet.

Absorbent products and containment Pads, pants, sheath catheters — not a treatment but improve quality of life and dignity while awaiting treatment response. Prescribable on FP10 (Conveen, Kylie, Tena range). NICE recommends these as interim measures.

Vaginal pessary for prolapse Ring or shelf pessary for POP-associated UI. Useful for women who decline or are unfit for surgery. Continence nurse specialist or GP with extended training can fit.

Psychological support UI has significant impact on mental health, sexual function, and social isolation. Screen for anxiety/depression (PHQ-9/GAD-7). CBT/mindfulness for OAB anxiety. Self-help resources: Bladder & Bowel UK charity.

Weight loss is the single most impactful intervention for overweight women with SUI — the PRIDE trial (NEJM 2009) showed a 47% reduction in incontinence episodes with ≥8% weight loss vs 28% in controls. Caffeine acts as a direct detrusor irritant and increases urine production — a RCT (Bryant 2002) showed reducing caffeine to <100 mg/day reduced urgency episodes by 25%. The Knack manoeuvre (contracting pelvic floor before coughing) reduces SUI by ~73% (Miller 2008). Squeezy NHS app is NICE-endorsed and improves PFMT adherence significantly. Lifestyle modification should never be presented as a "try this instead of treatment" — it IS the treatment.

9

Safety

Follow-Up, Monitoring & Safety-Netting

Done

Structured follow-up maximises treatment response and ensures red flags are not missed on re-presentation.

4–6 weeks

Review bladder diary (completed?). Assess PFMT compliance and technique. Check antimuscarinic / mirabegron tolerability. ICI-Q-SF score — document change from baseline. Review UTI culture results if sent. Reinforce lifestyle advice.

3 months

Full response assessment. Repeat ICI-Q-SF. If <50% improvement in SUI → referral for physiotherapist-supervised PFMT or urogynaecology. If <50% improvement in UUI on bladder training → consider antimuscarinic / mirabegron. Review medication dose / switch if poorly tolerated.

Antimuscarinics monitoring

Review at 4 weeks and 3 months. Check: cognitive function (especially elderly — use MMSE/MoCA if concerned), constipation, urinary retention symptoms, dry mouth, blurred vision. Stop if cognitive decline suspected

Mirabegron monitoring

Check BP before starting and at 4-week review. Contraindicated if BP >180/110. Monitor for urinary retention (especially if combined with antimuscarinic).

Topical oestrogen

Review at 3 months for response. Long-term use is safe — no scheduled monitoring required. Annual review of continuing need at medication review.

6–12 months

Consider stepping down if significant improvement. Reassess if symptoms recur. Remind patient that UI can recur after menopause, with weight gain, or with new medications.

Safety-net: 999

New bilateral leg weakness, saddle anaesthesia, inability to void, severe perineal pain → 999 (cauda equina). Symptoms of sepsis (high fever, rigors, confusion) with urinary symptoms → 999.

Safety-net: Same-day

Acute urinary retention (unable to pass urine, suprapubic pain). Frank haematuria in any patient not already on 2WW pathway. New neurological symptoms (leg weakness, loss of sensation) with UI.

Safety-net: Routine

Recurrence of haematuria. Worsening symptoms despite treatment. New pelvic pain. Symptoms of prolapse worsening. No improvement after 3 months conservative management.

QOF / Long-term

UI is not currently a QOF indicator but document: diagnosis, type, ICI-Q score, treatment offered, review date. Opportunistic review at annual chronic disease reviews (diabetes, hypertension, menopause).

Follow-up is essential because PFMT requires ≥3 months of correct technique — many patients do exercises incorrectly (bearing down instead of lifting). The 4-week antimuscarinic review catches early side effects before they become entrenched — particularly cognitive decline in elderly patients (MHRA 2021 guidance). Bladder malignancy can be missed if haematuria that appears on review is not acted upon — every episode of haematuria requires the 2WW pathway unless already referred. UI symptoms fluctuating after menopause or with weight changes is expected — safety-netting empowers patients to return appropriately rather than waiting years with unmanaged symptoms.